Seeking Alpha

Pharmacyclics' (PCYC) ibrutinib is granted a 3rd "Breakthrough Therapy Designation" by the FDA...

Pharmacyclics' (PCYC) ibrutinib is granted a 3rd "Breakthrough Therapy Designation" by the FDA for treatment of certain patients with leukemia and lymphoma. (PR)
Comments (2)
  • snakeriver83001
    , contributor
    Comments (3) | Send Message
     
    The real 'breakthrough' for this drug is most autoimmune indications.
    8 Apr 2013, 08:35 AM Reply Like
  • snakeriver83001
    , contributor
    Comments (3) | Send Message
     
    Just wait until they do an autoimmune study. That will be the 'real' break through of this drug.
    8 Apr 2013, 08:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|